@article{672ddef399df48fba6811ec0420baf52,
title = "Treatment-Resistant Late-Life Depression: A Review of Clinical Features, Neuropsychology, Neurobiology, and Treatment",
keywords = "Diagnosis, Neuromodulation, Neuropsychological factors, Older adults, Presentation, Treatment, Treatment-resistant depression",
author = "Subha Subramanian and Oughli, {Hanadi A.} and Gebara, {Marie Anne} and Palanca, {Ben Julian A.} and Lenze, {Eric J.}",
note = "Funding Information: S. Subramanian, M.A. Gebara, B.J.A. Palanca, and H.A. Oughli have no conflicts of interest to disclose. M.A Gebara receives support from Janssen and has received compensation from Otsuka for developing and presenting a disease-state webinar (not product-focused). E.J. Lenze reports consulting fees from Merck, Boehringer-Ingelheim, Pritikin ICR, IngenioRx, and Prodeo. E.J. Lenze also receives grant funding from Janssen, the COVID Early Treatment Fund , and FastGrants . E.J. Lenze has a patent pending on sigma-1 receptor agonists for COVID-19.",
year = "2023",
month = jun,
doi = "10.1016/j.psc.2023.02.008",
language = "English",
volume = "46",
pages = "371--389",
journal = "Psychiatric Clinics of North America",
issn = "0193-953X",
number = "2",
}